News in numbers Worldwide total prescription drug sales (2015–2030e) The pharma journey
1,800 1,600 1,400 1,200 1,000 800 600 400 200 0
24 21 18 15 12 9 6 3 0
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024e 2025e 2026e 2027e 2028e 2029e 2030e Sales Growth (right scale)
Notes: e - Estimate. Source: Evaluate Pharma’s ‘World Preview 2024’. Copyright 2025 by Standard & Poor’s Financial Services LLC. All rights reserved.
Estimated R&D expenditure of the top 50 pharmaceutical companies (2012–2026p)
225 200 175 150 125 100 75 50 25 0
203 190 178 156 137 105 106 107 107 119 121 123 126 6.7% 6.7% 167 216 0.0. %00 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022p 2023p 2024p 2025p 2026p
16% 14% 12% 10% 8% 6% 4% 2% 0
-2%
Notes: *p – Projected figures were calculated based on an average annual growth in Research & Development expenditure between 2018 and 2022 (6.7%)
Source: Centre for Medicines Research (CMR), Clarivate, 2024
globally in the past 20 years, targeting various disease areas, such as oncology, neurology, and infectious diseases.
285 6
3x
Innovation in the industry 942
by companies, as of July 2024, either in clinical trials or awaiting review by the FDA.
The number of CAR-T products approved by the FDA in 2024.
The amount, over the past 10 years, that industry-sponsored trials for cell
and gene therapy have risen. Source:
www.ifpma.org/publications/alwaysinnovating-pharmaceutical-industry-facts-figures World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Source:
www.ifpma.org/publications/alwaysinnovating- pharmaceutical-industry-facts-figures
9 26% -3
0.01–0.02% 10–15 years
The percentage of compounds (one or two out of every 10,000) synthesised in laboratories that successfully pass all development stages required to enter the market.
The estimated number of years it takes to develop a new medicine,with an average cost of USD 2.6 billion, when accounting for the cost of failures.
The percentage increase of the average time from clinical trial
start to patient enrolment close from 2019 to 2023, highlighting the growing complexity of pharmaceutical R&D.
USD167bn
The estimated spend in R&D in 2022 of the top 50 pharmaceutical companies. R&D spending has been increasing by almost 60% in the 10 years from 2012 to 2022.
Drug delivery timeline
The number of active substances (NASs) that have launched
69
The number of vaccines (preventive or therapeutic) under development
The number of substances (NASs) launched globally in 2023, six
more than the previous year. 12,700 6
The number, as of October 2024, of
medicines at different phases of clinical development globally, supported by the pharmaceutical industry, biotechs, academia and medical research charities.
The number of first-in-class cell and gene therapies that were launched during 2023, including one
for Duchenne muscular dystrophy (DMD) and one for Haemophilia A.
Preclinical Research (3–6 years)
Clinical
Development (6–7 years)
Regu atory
Regulatorl Review
Review (0.5–2(0.5–2 years)
years)
Annual change in expenditure
Global pharmaceutical expenditure (USDb)
US$ (Billions)
(%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
